INDIANAPOLIS (dpa-AFX) - Eli Lilly and Co. (LLY) announced Thursday positive
topline results from the QWINT-2 and QWINT-4 phase 3 clinical trials evaluating
once-weekly insulin efsitora alfa (efsitora) in adults with type 2 diabetes
using insulin for the first time (insulin naïve) and those who require multiple
daily insulin injections.

In the treat-to-target clinical trials, efsitora showed non-inferior A1C
reduction compared to the most commonly used daily basal insulins globally.

QWINT-2 evaluated the efficacy and safety of once-weekly efsitora compared to
once-daily insulin degludec for 52 weeks. The trial randomized insulin-naïve
adults with type 2 diabetes to receive efsitora once weekly or insulin degludec
once daily and was also designed to assess efficacy in patients using and not
using GLP-1 receptor agonists.

The trial met its primary endpoint of non-inferior A1C reduction with efsitora
compared to insulin degludec at week 52. In a key secondary endpoint, efsitora
was non-inferior to insulin degludec in A1C change among participants using and
not using GLP-1 receptor agonists.

QWINT-4 evaluated the efficacy and safety of efsitora compared to insulin
glargine for 26 weeks in adults with type 2 diabetes who have previously been
treated with basal insulin and at least two injections per day of mealtime
insulin. The trial randomized participants to receive efsitora once weekly or
insulin glargine once daily, both of which were administered with insulin
lispro.

The trial met its primary endpoint of non-inferior A1C reduction with efsitora
compared to insulin glargine at week 26.



Copyright(c) 2024 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX